AJP - Heart Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 283: H1863-H1872, 2002. First published June 27, 2002; doi:10.1152/ajpheart.01131.2001
0363-6135/02 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/5/H1863    most recent
01131.2001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liang, C.-S.
Right arrow Articles by Stevens, S. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liang, C.-S.
Right arrow Articles by Stevens, S. Y.
Vol. 283, Issue 5, H1863-H1872, November 2002

Differential pre- and postsynaptic effects of desipramine on cardiac sympathetic nerve terminals in RHF

Chang-Seng Liang, Yoshihiro Himura, Michihiro Kashiki, and Suzanne Y. Stevens

Cardiology Unit, Department of Medicine, and Department of Neurobiology and Anatomy, University of Rochester Medical Center, Rochester, New York 14642

Right heart failure (RHF) is characterized by chamber-specific reductions of myocardial norepinephrine (NE) reuptake, beta -receptor density, and profiles of cardiac sympathetic nerve ending neurotransmitters. To study the functional linkage between NE uptake and the pre- and postsynaptic changes, we administered desipramine (225 mg/day), a NE uptake inhibitor, to dogs with RHF produced by tricuspid avulsion and progressive pulmonary constriction or sham-operated dogs for 6 wk. Animals receiving no desipramine were studied as controls. We measured myocardial NE uptake activity using [3H]NE, beta -receptor density by [125I]iodocyanopindolol, inotropic responses to dobutamine, and noradrenergic terminal neurotransmitter profiles by glyoxylic acid-induced histofluorescence for catecholamines, and immunocytochemical staining for tyrosine hydroxylase and neuropeptide Y. Desipramine decreased myocardial NE uptake activity and had no effect on the resting hemodynamics in both RHF and sham animals but decreased myocardial beta -adrenoceptor density and beta -adrenergic inotropic responses in both ventricles of the RHF animals. However, desipramine treatment prevented the reduction of sympathetic neurotransmitter profiles in the failing heart. Our results indicate that NE uptake inhibition facilitates the reduction of myocardial beta -adrenoceptor density and beta -adrenergic subsensitivity in RHF, probably by increasing interstitial NE concentrations, but protects the cardiac noradrenergic nerve endings from damage, probably via blockade of NE-derived neurotoxic metabolites into the nerve endings.

congestive heart failure; neuronal norepinephrine uptake; tyrosine hydroxylase; neuropeptide Y


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C.-s. Liang, W. Mao, C. Iwai, S. Fukuoka, and S. Y. Stevens
Cardiac sympathetic neuroprotective effect of desipramine in tachycardia-induced cardiomyopathy
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H995 - H1003.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. Mao, F. Qin, C. Iwai, R. Vulapalli, P. C. Keng, and C.-s. Liang
Extracellular norepinephrine reduces neuronal uptake of norepinephrine by oxidative stress in PC12 cells
Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H29 - H39.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C.-s. Liang
Sympatholysis and cardiac sympathetic nerve function in the treatment of congestive heart failure
J. Am. Coll. Cardiol., August 6, 2003; 42(3): 549 - 551.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C.-s. Liang, A. Yatani, Y. Himura, M. Kashiki, and S. Y. Stevens
Desipramine attenuates loss of cardiac sympathetic neurotransmitters produced by congestive heart failure and NE infusion
Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1729 - H1736.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online